This composite educational graphic details the Alzheimer's Disease (AD) continuum and associated neuroanatomy. Section A presents a flowchart of the AD continuum across five stages: Consciousness, Chronic Stress, Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI), and AD. Thick forward-pointing arrows indicate the progression towards dementia, while thinner reverse arrows suggest potential reversibility in early stages (prior to reaching the AD stage). Section B is a labeled anatomical diagram of a medial sagittal section of the human brain. Key structures highlighted include the Prefrontal Cortex, Cingulate Cortex, Nucleus Accumbens, Amygdala, Claustrum, and Hippocampus. The diagram illustrates the spatial relationship between these cortical and subcortical regions involved in emotion, consciousness, and memory, emphasizing their role in the pathophysiological progression from early cognitive symptoms to clinically diagnosed Alzheimer's Disease. This resource serves to visualize the transition from emotional and behavioral changes to cognitive decline and irreversible neurodegeneration.

This infographic presents a multimodal imaging signature of Subjective Cognitive Decline (SCD) in the context of Alzheimer's disease progression. It displays five distinct neuroimaging modalities mapped onto a sagittal brain template. (A) Amyloid-PET highlights amyloid accumulation in red within the medial prefrontal cortex, cingulate cortex, and precuneus. (B) FDG-PET illustrates hypometabolism in blue, primarily affecting the medial temporal lobe and precuneus. (C) T1-MRI identifies structural changes in purple, specifically reduced volume in the hippocampus and thinning of the entorhinal cortex. (D) fMRI depicts abnormal functional connectivity in orange, focusing on the posterior Default Mode Network (DMN) and related cortical regions. (E) Diffusion Tensor Imaging (DTI) shows decreased fractional anisotropy (FA) in green, indicating white matter microstructural deficits in the hippocampal and parahippocampal areas. This comparative visual serves as a summary of molecular, structural, and functional biomarkers used to identify early neuroanatomical vulnerability in preclinical stages of dementia.

This infographic illustrates the neuroanatomical and multifractal changes across three stages of cognitive decline in the ADNI dataset: Cognitively Normal (CN), Mild Cognitive Impairment (MCI), and Alzheimer's Disease (AD). The visual is organized into a matrix comparing T2-weighted axial brain MRI slices (Source Image) with their corresponding singularity spectrum plots (f(α) spectrum). Clinical Imaging Findings: - CN: Shows normal brain volume with well-defined sulci and standard ventricular size. - MCI: Exhibits subtle cortical atrophy and mild ventricular enlargement. - AD: Demonstrates significant global cerebral atrophy, marked widening of the sulci, and pronounced ventriculomegaly, indicating substantial loss of brain tissue and increased cerebrospinal fluid (CSF) volume. Multifractal Analysis: The f(α) spectrum plots quantify structural complexity. As the disease progresses from CN to AD, the curves shift to the right (higher Alpha values) and become significantly broader. This widening indicates increased structural heterogeneity and irregularity within the brain tissue, serving as a mathematical signature for the pathological progression of Alzheimer's dementia.

A multi-panel educational composite illustrating the cholinergic system in health and Alzheimer’s Disease (AD). (A) Sagittal anatomical diagram of the human brain showing cholinotrophic projection systems from cholinergic cell groups Ch1 (medial septal), Ch2 (diagonal band), and Ch4 (nucleus basalis) to the neocortex and hippocampus (Hip). (B-D) Photomicrographs comparing basal forebrain neurons: (B) healthy aged control with high neuron density; (C) AD sample showing significant neuronal loss and atrophy; (D) Thioflavin-S fluorescent staining identifying neurofibrillary tangles in p75NTR neurons. (E-G) Pathophysiology diagrams of the cholinergic synapse: (E) normal acetylcholine (ACh) synthesis via ChAT and degradation via AChE; (F) reduced ACh levels typical of AD pathology; and (G) the therapeutic mechanism of acetylcholinesterase inhibitors (AChEIs), which block AChE to increase synaptic ACh availability. The content highlights the neuroanatomical basis, histopathological changes, and pharmacological interventions relevant to dementia and neurodegeneration.

This medical infographic illustrates the multi-target-directed ligand (MTDL) mechanism of the drug protriptyline in the context of Alzheimer's Disease (AD) pathogenesis. Set against the anatomical backdrop of a human brain, the central 3D molecular structure of protriptyline is shown radiating inhibitory T-bars towards four primary pathological targets. 1) BACE-1 Inhibition: Depicts the blockade of beta-secretase-mediated cleavage of amyloid precursor protein, preventing Amyloid-beta (Aβ) formation. 2) Amyloid Aggregation Inhibition: Shows a red 'X' blocking the transition of Aβ monomers (blue spheres) into neurotoxic oligomeric aggregates. 3) Acetylcholinesterase (AChE) Inhibition: Illustrates the prevention of acetylcholine breakdown into acetyl and choline, maintaining neurotransmitter levels. 4) Glycation Inhibition: Demonstrates the inhibition of glucose (Glu) reacting with Aβ peptides, a process that normally exacerbates amyloid toxicity. The diagram emphasizes the drug's therapeutic potential to concurrently address enzymatic dysfunction, protein misfolding, and metabolic complications associated with neurodegeneration.